The difference of double-positive T cells and double-negative-T cells in myeloid neoplasms before and after chemotherapy, and after COVID-19 infection

Abstract

Abstract T lymphocytes play a crucial role in the immunological microenvironment of tumors by performing several roles, such as regulating immune responses and executing cytotoxic attacks on tumor cells. However, it is worth noting that various subpopulations of T cells might exhibit contrasting functions in the advancement of tumors, particularly in the context of hematological malignancies. In this study, we studied the differential expression levels of CD3 + CD4 + CD8 + T (double-positive T cells, DPT) cells and CD3 + CD4-CD8-T (double-negative T cells, DNT) cells in myeloid neoplasms, with a particular focus on the pre- and post-chemotherapy stages in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study focused on alterations in the peripheral blood composition of patients with AML/MDS before and after COVID-19 infection, aiming to investigate the clinical relevance of DPT cells and DNT cells in myeloid neoplasms and COVID-19 infection. Additionally, the study aimed to offer insights for future research on the prognosis, diagnosis, and treatment of myeloid neoplasms.